Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 23;72(7):2099–2111. doi: 10.1007/s00262-023-03383-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — KIR2DL2+/HLA-C1+ patients have significantly greater clinical benefit compared to patients who are not KIR2DL2+/HLA-C1+. Kaplan–Meier curve for PFS (a) compares patients who are KIR2DL2+/HLA-C1+ (red line) to patients who are not KIR2DL2+/HLA-C1+ (blue line). Waterfall plots displaying OR and tumor shrinkage (b) compares patients who are KIR2DL2+/HLA-C1+ (right) with patients who are not KIR2DL2+/HLA-C1+ (left). CBOR is the confirmed best overall response by RECIST 1.1 criteria; PD, progressive disease (light orange); SD, stable disease (orange); PR, partial response (purple); CR, complete response (light purple). Vertical dotted lines divide the number of patients into thirds, and horizontal dotted lines indicate a +20% increase and −30% decrease in target lesion size from baseline. The dotted red box outlines the top third of patients, indicating a larger proportion of patients with a positive clinical response in the KIR2DL2+/HLA-C1+ group (right) than in the group who are not KIR2DL2+/HLA-C1+ (left)